MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11136-015-0985-8

Медицинская библиотека · Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2015

Quality of life changes in patients undergoing treatment for hepatocellular carcinoma.

Chie Wei-Chu, Yu Fang, Li Mengqian, Baccaglini Lorena, Blazeby Jane M, Hsiao Chin-Fu, Chiu Herng-Chia, Poon Ronnie T, Mikoshiba Naoko, Al-Kadhimi Gillian, Heaton Nigel, Calara Jozer, Collins Peter, Caddick Katharine, Costantini Anna, Vilgrain Valerie, Chiang Chieh

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. One of the primary treatment goals for incurable advanced cases is to prolong quality of life (QoL). Thus, to determine which HCC therapies may be linked to a more favorable QoL, we assessed the association between QoL changes and different treatments in HCC patients.

METHODS

We analyzed a non-randomized multicenter longitudinal study, which included 171 patients treated with surgery (n = 53), ablation (n = 53) or embolization (n = 65) from seven centers: four Asian and three European sites. All participants completed the EORTC QLQ-C30 and QLQ-HCC18 questionnaires before and after treatment. Propensity scores were calculated and used in addition to race for adjustment in the logistic regression model to account for the confounding effects of patient characteristics including age, gender, race, employment, living with family, at least one comorbid condition, years since diagnosis, prior treatment history, BCLC stage, Child-Pugh grade, cirrhosis, bilirubin levels and QoL score before treatment.

RESULTS

After adjustment for confounders, patients tended to have higher odds of QoL deterioration when treated with ablation versus embolization (dyspnea: p = 0.019; appetite loss: p = 0.018; body image: p = 0.035) or ablation versus surgery (dyspnea: p = 0.099; appetite loss: p = 0.100; body image: p = 0.038).

CONCLUSIONS

There were significant differences in QoL deterioration across different treatment groups. This information may assist patients and providers when selecting patient-centered treatment approaches for HCC.

Для цитирования: Chie Wei-Chu, Yu Fang, Li Mengqian, Baccaglini Lorena, Blazeby Jane M, Hsiao Chin-Fu, Chiu Herng-Chia, Poon Ronnie T, Mikoshiba Naoko, Al-Kadhimi Gillian, Heaton Nigel, Calara Jozer, Collins Peter, Caddick Katharine, Costantini Anna, Vilgrain Valerie, Chiang Chieh. Quality of life changes in patients undergoing treatment for hepatocellular carcinoma.. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2015. DOI: 10.1007/s11136-015-0985-8.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.